Publication:
The rationale and design of the national peripartum cardiomyopathy registries in Turkey: the Artemis-I and Artemis-II studies

dc.contributor.coauthorKayikcioglu, Meral
dc.contributor.coauthorTokgozoglu, Lale
dc.contributor.coauthorUral, Dilek
dc.contributor.coauthorBiteker, Murat
dc.contributor.departmentN/A
dc.contributor.kuauthorMutluer, Ferit Onur
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T23:49:16Z
dc.date.issued2018
dc.description.abstractObjective: Peripartum cardiomyopathy (PPCM) is left ventricular (LV) systolic dysfunction with an ejection fraction of <= 45% occurring in the later stages of pregnancy or soon after delivery. Although various risk factors have been identified, the exact cause of the disease is unknown. Unlike most countries in the European region, Turkey has yet to determine the current PPCM burden. A registry for this purpose does not exist. To close this gap, the A RegisTry of pEripartuM cardIomyopathy in Turkish patientS (ARTEMIS-I and ARTEMIS-II), was planned and endorsed by the Turkish Society of Cardiology. The aim of this manuscript is to describe the rationale and design of the ARTEMIS-I and ARTEMIS-II registries. Methods: ARTEMIS was designed to be the nationwide PPCM registry of Turkey, with the goal of identifying problems and opportunities while improving quality and consistency in the medical care of PPCM patients. A second goal is to determine the clinical characteristics pertinent to patients in this region. The ARTEMIS registry will consist of 2 arms. All secondary and tertiary cardiology centers have been electronically invited to participate in ARTEMIS-I, which will be conducted to assess the current standard of care and outcome measures. Centers will be asked to enroll PPCM patients admitted to their clinic in last 5 years retrospectively. Eligibility criteria will consist of pregnant or early postpartum woman without a previous history of heart failure (HF) or known pathology associated with HF, LV ejection fraction <= 45%, and exclusion of other causes of LV systolic dysfunction. ARTEMIS-II will consist of the prospective enrollment of patients. Conclusion: The nationwide PPCM registries, ARTEMIS-I and ARTEMIS-II, are designed to determine the current status of medical care, provide insights into nature of the disease, and suggest solutions on how to improve care and outcomes in these patients.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyTR Dizin
dc.description.issue1
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsorshipAbbott
dc.description.sponsorshipAbdi Ibrahim
dc.description.sponsorshipActelion
dc.description.sponsorshipAegerion
dc.description.sponsorshipAmgen
dc.description.sponsorshipBayer Schering
dc.description.sponsorshipMerck
dc.description.sponsorshipSanofi
dc.description.sponsorshipPfizer
dc.description.sponsorshipRecordati
dc.description.sponsorshipAstra
dc.description.sponsorshipNovartis
dc.description.sponsorshipDaiichi Sankyo
dc.description.sponsorshipServier
dc.description.sponsorshipBoehringer Ingelheim
dc.description.sponsorshipBayer
dc.description.sponsorshipGlaxoSmithKline
dc.description.sponsorshipMenarini
dc.description.sponsorshipKowa
dc.description.sponsorshipSynageva Prof. Meral Kayikcioglu, M.D., has received honoraria (lectures and counseling) and / or research funding from Abbott, Abdi Ibrahim, Actelion, Aegerion, Amgen, Bayer Schering, Merck, Sanofi, Pfizer, Recordati
dc.description.sponsorshipProf. Lale Tokgozoglu, M.D., has received honoraria / consultancy fees from Merck, Amgen, Astra, Novartis, Abbott, Daiichi Sankyo, Pfizer, Actelion, Servier, Sanofi, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Menarini, Kowa, Aegerion, and Synageva
dc.description.sponsorshipFerit Onur Mutluer, M.D., None
dc.description.sponsorshipProf. Dilek Ural, M.D., has received honoraria (for lectures and consultancy) from Abdi Ibrahim, Amgen, Merck, and Novartis during the last 2 years
dc.description.sponsorshipAssoc. Dr. Murat Biteker, M.D., has received honoraria (for lectures and consultancy) from Abbott, Abdi Ibrahim, Bayer, and Pfizer for the last 2 years.
dc.description.volume46
dc.identifier.doi10.5543/tkda.2018.53248
dc.identifier.issn1016-5169
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85040785256
dc.identifier.urihttp://dx.doi.org/10.5543/tkda.2018.53248
dc.identifier.urihttps://hdl.handle.net/20.500.14288/14346
dc.identifier.wos429103400007
dc.keywordsPeripartum cardiomyopathy
dc.keywordsRegistry
dc.keywordsTurkey
dc.keywordsHeart-failure association
dc.keywordsCardiology working group
dc.keywordsClinical characteristics
dc.keywordsWorldwide registry
dc.keywordsEuropean-society
dc.keywordsCurrent state
dc.keywordsPredictors
dc.keywordsRecovery
dc.keywordsBromocriptine
dc.keywordsPregnancy
dc.languageEnglish
dc.publisherAves
dc.sourceTurk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
dc.subjectCardiac and cardiovascular systems
dc.titleThe rationale and design of the national peripartum cardiomyopathy registries in Turkey: the Artemis-I and Artemis-II studies
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0001-9114-9529
local.contributor.kuauthorMutluer, Ferit Onur

Files